Introduction
Oral anticoagulation is the cornerstone in stroke prevention in atrial fibrillation (AF). Traditional treatment consists of a vitamin K antagonist (VKA) such as warfarin, an inexpensive drug that blocks the vitamin K-dependent liver production of coagulation factors II (prothrombin), VII, IX, and X in the plasma. More recently, nonvitamin K antagonist oral anticoagulants (NOACs), either direct factor Xa inhibitors (FXaIs) or direct thrombin inhibitors (DTIs), have been made available. Compared with NOACs, VKA has a relatively narrow therapeutic window. Therefore, VKA requires close monitoring: overdosing may result in life-threatening bleeding and underdosing in inefficacy. Monitoring of the intensity of anticoagulation, using the international normalized ratio (INR), 1,2 remains problematic and less than two-thirds of patients on chronic VKA therapy are within the therapeutic window. 3 Nevertheless, the latest data from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) show that VKA continues to be frequently prescribed. 4 In the past decades, antiplatelet (AP) therapy has been tested as an alternative to VKA for stroke prevention in AF. Although easy and patient friendly, aspirin monotherapy or in combination with clopidogrel has proved to be neither safer nor superior to VKA for the prevention of stroke. 5, 6 Therefore, the 2014 American guidelines on the management of AF advise low-dose aspirin as an alternative to VKA monotherapy in patients at a low stroke risk, but the recommendation is weak (IIb). 1 In addition, the 2016 European guidelines discourage the routine use of AP therapy altogether. 2 Yet, because of its ease of use and perceived safety, AP monotherapy, especially low-dose aspirin, is still prescribed in 12-61% of patients with AF, despite their increased stroke risk. 4, [7] [8] [9] [10] [11] [12] For many frail and elderly patients with AF (with not only a high risk of thromboembolism but also of haemorrhagic complications), such a strategy often seems an attractive alternative to oral anticoagulation. 13, 14 Therefore, we sought to analyse the prescribing pattern of AP monotherapy or in combination with oral anticoagulants (ACs) over the past 6 years by specialist and general practitioners using data from GARFIELD-AF, a prospective non-interventional registry of more than 50 000 consecutive patients with newly diagnosed AF and > _1 investigator-determined stroke risk factor. 15 The study not only included the analysis of patients' characteristics, but also clinical and economic factors that impact on the prescribing of AP monotherapy or in combination with oral ACs.
Methods

Study design and participants
Men and women > _18 years of age with non-valvular AF diagnosed according to standard local procedures within the previous 6 weeks, and with at least one risk factor for stroke as judged by the investigator, were eligible for inclusion. 16 Risk factors were not prespecified in the protocol nor were they limited to the components of existing risk stratification schemes. The study excluded patients with a transient reversible cause of non-valvular AF and those for whom follow-up is not envisaged or possible. To minimize recruitment bias in GARFIELD-AF, investigator sites have been selected randomly (apart from 18 sites, out of >1000) and represent the different care settings in each participating country. 15, 16 To study the evolution of antithrombotic management, consecutive patients were enrolled prospectively into five sequential cohorts from March 2010 to July 2016. The data were extracted from the study database on 28 Antithrombotic treatment patterns at baseline are displayed by enrolment period, by enrolment period and the presence or absence of indications for AP therapy (history of peripheral vascular artery disease, of ACS, of CAD, of stroke, of carotid occlusive disease, or of stenting), and by CHA 2 DS 2 -VASc score and country economic status (high-or upper middle-income). Cochrane-Armitage tests were used to test the trend in treatment patterns over time.
Hierarchical logistic regression models, accounting for random effects at the country level and the care setting level, were used to assess the impact of risk factors on prescribing of AP monotherapy (vs. AC monotherapy). Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs).
Risk factors in the models were selected by stepwise selection, with a = 0.05 for exclusion, from among the following baseline patient characteristics: age, ethnicity, gender, smoking, alcohol use, body mass index (BMI), type of AF at diagnosis, systolic and diastolic blood pressures, heart rate, history of CAD, history of ACS, history of bleeding, coronary artery bypass graft, vascular disease, CHF, hyperthyroidism, hypothyroidism, peripheral vascular disease, moderate-to-severe CKD, history of hypertension, diabetes mellitus, stroke/transient ischaemic attack, systemic embolism, cirrhosis, and dementia. Continuous variables were tested for linearity, and non-linear relationships were accounted for using linear splines.
Five imputation data sets were generated using a multiple imputation procedure 22, 23 assuming arbitrary missing patterns and applying a fully conditional specification method that assumes a joint distribution for all of the variables. The stepwise regression was performed using the first imputed data set. ORs with 95% CIs were calculated across the five imputed data sets, using parameter estimates as well as the withinand between-data set covariance matrices.
Data analysis was performed at the Thrombosis Research Institute with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics of patients receiving different antithrombotic therapies
Between March 2010 and July 2016, a total of 51 270 patients were enrolled prospectively in five cohorts from 35 countries. Overall, 20.7% of patients received AP monotherapy, 52.1% AC monotherapy, 14.1% AP with AC, 12.0% no antithrombotic treatment, and in 1.1% of patients the antithrombotic treatment was not defined. Most patients receiving AP monotherapy or AC monotherapy were diagnosed in the hospital setting (66.7% and 53.7%, respectively) or in an office (22.6% and 34.7%, respectively). Baseline characteristics of the AP monotherapy and AC monotherapy groups are shown in Table 1 . The median age of the AP monotherapy and AC monotherapy patients were 69.0 and 72.0 years, respectively. In both groups, most patients had new-onset (unclassified) AF (49.0% and 41.8%) or paroxysmal AF (29.9% and 26.2%). Most patients were Caucasian (52.3% and 67.1%), and the median BMI was 27.0 kg/m 2 for both AP monotherapy and AC monotherapy patients. The majority of patients recruited had a moderate-to-high risk of stroke (CHA 2 DS 2 -VASc score > _2; AP monotherapy, 82.5%; AC monotherapy, 86.8%). Less than 3% of patients in either treatment group were very lowrisk patients (CHA 2 DS 2 -VASc score 0). Most patients on AP monotherapy or AC monotherapy had their treatment funded by public insurance (71.3% and 81.9%, respectively). However, a greater proportion of the AP monotherapy patients paid for their treatment out of pocket (11.0% vs. 2.8% of AC monotherapy patients).
Of the patients on AP monotherapy, 42.7% had indications for AP. Compared to patients with no indications, they were older at AF diagnosis, less likely to be non-Chinese Asian or Hispanic/Latino, and more likely to be Caucasian or Chinese ( Table 2 ). The group with indications also showed a higher prevalence of cardiovascular conditions (CHF, history of hypertension, hypercholesterolaemia, history of bleeding), moderate-to-severe CKD, and diabetes. They had a higher median CHA 2 DS 2 -VASc score (4.0 vs. 2.0) but similar median HAS-BLED score to patients without indications (2.0 for both). Aspirin monotherapy was the main AP therapy prescribed to patients on AP monotherapy (68.7%) or patients on AP with AC therapy (65.2%). A small proportion of patients received monotherapy with adenosine diphosphate receptor or P2Y 12 inhibitors (AP monotherapy, 7.0%; AP þ AC, 10.3%) or dual therapy with aspirin (AP monotherapy, 11.3%; AP þ AC, 7.6%).
Temporal change in prescription of antithrombotic therapies
The prescription of antithrombotic therapies in the five sequential cohorts of GARFIELD-AF is shown in Figure 1 . With each successive cohort, the prescription of AP monotherapy declined significantly, from 30.2% in Cohort 1 (2010-2011) to 16.3% in Cohort 5 (2015-2016) (P < 0.0001). In contrast, there was no change over time in the proportion of patients receiving AP therapy with AC therapy or no antithrombotic therapy.
The prescription of AP monotherapy, aspirin monotherapy, and AP therapy with or without AC therapy over time was analysed according to the presence or absence of indications for AP therapy. In the patients receiving AP monotherapy, there was a substantial drop in non-indicated use, from 18.9% in Cohort 1 (2010-2011) to 8.5% in Cohort 5 (2015 Cohort 5 ( -2016 , while the change in indicated use was much less. However, even in Cohort 5 (2015 Cohort 5 ( -2016 , approximately 50% of the patients treated with AP monotherapy had no indication except AF ( Figure 2A ) and of these patients, 70.6% had a CHA 2 DS 2 -VASc of > _2. The trend over time of a decline in non-indicated use, but little change in indicated use was also observed in the patients prescribed aspirin monotherapy ( Figure 2B ) and in the patients prescribed AP therapy with or without AC therapy ( Figure 2C ).
Prescription of antithrombotic therapies by CHA 2 DS 2 -VASc score and country economic status
The prescription of antithrombotic therapies was also analysed according to stroke risk (CHA 2 DS 2 -VASc score) and economic status of the country in which patients were recruited ( Figure 3) . For all CHA 2 DS 2 -VASc categories, the prescription of AP monotherapy was greater in upper middle-income countries than in high-income countries, while NOAC prescribing with or without AP therapy was lower in upper middle-income countries. Conversely, the prescription of VKA (with or without AP therapy) was similar in upper 
Predictors for prescription of antiplatelet monotherapy vs. anticoagulant monotherapy
Predictors for a prescription of AP monotherapy vs. AC monotherapy are presented as a forest plot where an OR >1 favours AP prescribing and <1 favours AC prescribing (Figure 4) . 
Discussion
This study reports for the first time worldwide the relation of AP monotherapy to vascular indications for AP therapy in patients with AF at risk for stroke. The main findings can be summarized as follows: (i) at the start of this large, long-term, prospective registry, about 20% of patients were prescribed AP monotherapy for stroke prevention without an indication for AP therapy such as peripheral vascular disease, coronary disease, or cerebrovascular disease; (ii) despite the proliferation of American and European guidelines for the management of AF this figure was, 5 years later, still about 9% and the group represented over half of the patients on AP monotherapy; and (iii) AP monotherapy was seen more often in economically less well-off countries than in high-income areas.
Although oral anticoagulation is the standard of care for stroke prevention in patients with AF and a moderate-to-high risk of stroke, AP therapy is perceived as a safer albeit less effective alternative to oral anticoagulation. Aspirin therapy showed a modest but significant 22% relative reduction in the risk of thromboembolism in AF compared with placebo in a 2002 meta-analysis. 5 However, in direct comparisons in that meta-analysis, warfarin performed much better than aspirin, with a very significant relative risk reduction of 36%. These findings were confirmed in the only prospective randomized headto-head trial in the very elderly (mean age 82 years), where warfarin was more effective than aspirin for stroke prevention, but aspirin had the same bleeding complications as warfarin. 24 The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE)-A study showed in anticoagulation-ineligible patients that the combination of clopidogrel and aspirin was more effective than aspirin alone, but it caused more major bleeding, especially intracranial bleeding. 25 However, in a head-to-head comparison with warfarin in the ACTIVE-W trial, the aspirin-clopidogrel combination performed worse, with similar bleeding. 6 This is the reason that Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants aspirin monotherapy and the aspirin-clopidogrel combination are discouraged in anticoagulation-eligible patients in the most recent guidelines, and also in patients with AF who are ineligible for VKA. In the current report, data on non-indicated AP use in AF were collected in over 51 000 patients in 35 countries. The only other study investigating the same issue is the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry carried out in the USA in 10 176 patients with AF. It also showed that nearly 40% of patients still received AP therapy without a clear indication other than stroke prevention. 27 In the GARFIELD-AF registry, about half of the reasons why VKAs are withheld in patients eligible for anticoagulation are physicians' decisions. 15 They vary from perceived low stroke risk, risk of bleeding, falling, or fear of low compliance to guideline recommendations. It is probable that the fear of bleeding in patients on AP has had an influence in our current analysis. Although the use of non-indicated AP monotherapy has decreased over time in absolute numbers, the percentage of these patients is still around 50% (Figure 2A ) despite the evolution of AF guidelines. Further education of physicians is needed on the value of alternative antithrombotics to AP monotherapy. NOACs, for example, could be an option, especially when polypharmacy hampers the use of VKA. 28 
Limitations
Clearly, registries have their limitations given the inherent selection bias. Furthermore, only patients with newly diagnosed AF (of less than 6 weeks' duration) and a perceived increased risk of stroke were included. These restrictions may have skewed the results on the use of AP monotherapy. Without these limitations, the use of AP monotherapy would have been even higher. In addition, changes in antithrombotic therapy during follow-up have not been included, but will be analysed in further investigations. We excluded patients on both AC and AP, because they are protected against thromboembolism with the guideline-mandated AC. Finally, other factors that may have specifically precluded the use of AC like frailty 29 have not been prospectively taken into account.
Conclusion
In one of the largest, worldwide registries of patients with AF, there was no reason for prescribing AP drugs other than stroke prevention in over half of the patients receiving AP monotherapy. This is despite the fact that AP monotherapy is no longer recommended as a substitute for oral anticoagulation for patients with AF at low risk of stroke. Since this change in guidance and the advent of NOACs, the prescribing of AP monotherapy in newly diagnosed patients with AF has diminished, but it still remains a prominent part of the management of patients with AF, especially in upper middle-income countries.
Supplementary material
Supplementary material is available at European Heart Journal online.
